TGTX Q3 2023 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$166M+176298.9% YoY

Gross Profit

$162M97.9% margin

Operating Income

$115M69.2% margin

Net Income

$114M68.7% margin

EPS (Diluted)

$0.73

QoQ Revenue Growth

+931.6%

Cash Flow

Operating Cash Flow

$84M

Free Cash Flow

$84M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$331M

Total Liabilities

$166M

Stockholders' Equity

$165M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$166M	$94,000	+176298.9%
Gross Profit	$162M	$92,000	+176319.6%
Operating Income	$115M	-$35M	+428.3%
Net Income	$114M	-$36M	+418.1%

Revenue Segments

License

$141M85%

Product

$25M15%